JCR Pharma achieved net sales of 9,700 million yen in the first quarter of FY2027, a 13.2% increase YoY, with gross profit reaching 7,450 million yen, a 19.9% YoY increase. Research and development expenses and selling expenses also increased, leading to an operating income of 2,103 million yen, significantly expanding profitability.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4552-20260730-01.pdf","jir_short_summary":"JCR Pharma achieved net sales of 9,700 million yen in the first quarter of FY2027, a 13.2% increase YoY, with gross profit reaching 7,450 million yen, a 19.9% YoY increase. Research and development expenses and selling expenses also increased, leading to an operating income of 2,103 million yen, significantly expanding profitability.","jir_summary":"### Performance Overview\nIn the first quarter of FY2027, JCR Pharma recorded net sales of 9,700 million yen (up 13.2% YoY), and gross profit of 7,450 million yen (up 19.9% YoY). Although research and development expenses and selling expenses increased, operating income expanded significantly to 2,103 million yen, showing improved profitability. The growth is driven by expanded pharmaceutical sales and proactive research investments.\n\n### Future Outlook and Investor Impact\nThe company plans to continue strengthening its research, development, and sales activities to expand sales and profits. Approval of new drugs and progress in overseas expansion are expected to support long-term growth. For investors, increased profitability and active research investment are viewed as value-enhancing strategies for the company.","jir_financial_highlights":"Net Sales: 9,700 million yen (YoY +13.2%)\nGross Profit: 7,450 million yen (YoY +19.9%)\nOperating Income: 2,103 million yen (YoY +85.4%)","jir_category":"","jir_hashtags":"#JCRPharma, #FinancialResults, #JapanStocks","jir_key_figures":"Net Sales: 9,700 million yen (YoY +13.2%)\nGross Profit: 7,450 million yen (YoY +19.9%)\nOperating Income: 2,103 million yen (YoY +85.4%)","jir_meta_title":"\u3010JCR Pharma\u3011FY2027 Q1 Financial Results \u2014 Net Sales 9,700 million yen (+13.2%)","jir_meta_description":"JCR Pharma reported net sales of 9,700 million yen (up 13.2% YoY) in Q1 FY2027, with profit growth. Insights into future growth strategies and investment points are provided.","jir_og_title":"\u3010JCR Pharma\u3011Q1 FY2027 Results \u2014 Net Sales 9,700 million yen Increase in Profit","jir_og_description":"Overview of JCR Pharma's FY2027 Q1 results and future outlook. Highlights of sales increase and profit expansion are shared for investors.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Q1 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Net Sales\\\", \\\"data\\\": [9700], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Q1 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Income\\\", \\\"data\\\": [2103], \\\"borderColor\\\": \\\"#4BC0C0\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Composition\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Domestic\\\", \\\"Overseas\\\"], \\\"datasets\\\": [{\\\"data\\\": [\u4e0d\u660e, \u4e0d\u660e], \\\"backgroundColor\\\": [\\\"#FF6384\\\", \\\"#36A2EB\\\"]}]} \"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Q1 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Gross Profit Margin\\\", \\\"data\\\": [\u4e0d\u660e], \\\"backgroundColor\\\": \\\"#FFCE56\\\"}]} \"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"[]\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90546","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n